Navigation Links
FDA Gives Approval for Skin Cancer Drug, Zolinza

Zolinza, the most recent skin cancer drug has today received approval from the U.S. Food and Drug Administration (FDA). Zolinza (vorinostat) capsules is mainly recommended// for the treatment of cutaneous T-cell lymphoma (CTCL) type of skin cancer when the disease persists, worsens, or returns during or after treatment with other medicines.

Zolinza has been approved as part of FDA's Orphan Drug program that offers companies financial incentives to develop medications for diseases which affect less than 200,000 American patients a year. About three in every one million people are diagnosed with CTCL each year in the United States. Most of those afflicted with CTCL are men with an average age of 50 years.

Steven Galson, M.D., director of FDA's Center for Drug Evaluation and Research said, "This approval is another example of the benefits of modern research that's focused on providing prescribers with safe and effective therapies for all types of cancer, including those that affect relatively few patients."

Two clinical trials that were conducted with 107 CTCL patients gave evidence of Zolinza's safety and effectiveness. These patients were treated with Zolinza following return of their disease following other treatments.

30 percent of patients who received Zolinza observed an improvement in a scale that was defined by scoring of skin lesions and lasted an average of 168 days.

Some of the most common serious adverse events that occurred were pulmonary embolism, deep vein thrombosis, dehydration, and anemia. Some of most common other adverse events were gastrointestinal symptoms such as nausea, diarrhea, vomiting, anorexia and constipation; fatigue; chills; and taste disorders.

However Zolinza has shown probable fetal harm if administered during pregnancy according to results of animal studies.

Zolinza is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., Whitehouse Station, N.J.
NLA
'"/>




Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. FDA Gives Its Approval For Inhaler
11. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... industry. Conventional sodium testing methods are complicated and require expert user knowledge. In ... new analytical method dedicated to the simplified, yet highly accurate, determination of sodium. ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... Harris ... hard of hearing, is bringing its latest products to the Deaf Seniors of America ... will have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications ...
(Date:3/25/2017)... ... 25, 2017 , ... Norland at Swissray is pleased to announce the release of ... The ELITE DXA has an active scan window, which is more than double that of ... the scan area could not undergo an accurate total body bone density or body composition ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
Breaking Medicine Technology: